Curis (CRIS)
(Real Time Quote from BATS)
$9.38 USD
-0.29 (-3.00%)
Updated Jun 7, 2024 02:06 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Brokerage Reports
0 items in cart
Curis, Inc. [CRIS]
Reports for Purchase
Showing records 221 - 240 ( 303 total )
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Adding to Focus List on Erivedge Growth and Network Disruption Potential
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Partner Debiopharm Initiates Phase Ib Study, as Expected
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
4Q11 UPDATE - ERIVEDGE APPROVED - POTENTIAL BILLION DOLLAR MARKET
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
4Q11 UPDATE - ERIVEDGE APPROVED - POTENTIAL BILLION DOLLAR MARKET
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2011 Results; First Product Approved, Stream of Data Coming Up
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
KA-CHING!! A FIRST-IN-CLASS HEDGEHOG INHIBITOR RECEIVES FDA APPROVAL
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
KA-CHING!! A FIRST-IN-CLASS HEDGEHOG INHIBITOR RECEIVES FDA APPROVAL
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
ENDING 2011 WITH A BANG!! POTENTIAL FOR 2 APPROVALS IN 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
ENDING 2011 WITH A BANG!! POTENTIAL FOR 2 APPROVALS IN 2012
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
DUAL PI3K/HDAC INHIBITOR MAKES DEBUT IN HEMATOLOGICAL MALIGNANCIES
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
DUAL PI3K/HDAC INHIBITOR MAKES DEBUT IN HEMATOLOGICAL MALIGNANCIES
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
VISMODEGIB RECEIVES PRIORITY REVIEW - $8MM MILESTONE - NO ODAC!
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
VISMODEGIB RECEIVES PRIORITY REVIEW - $8MM MILESTONE - NO ODAC!
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q11 UPDATE - VISMODEGIB MILESTONES TO DRIVE VALUE NEAR-TERM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q11 UPDATE - VISMODEGIB MILESTONES TO DRIVE VALUE NEAR-TERM
Provider: RODMAN & RENSHAW, CO.
Analyst: BENJAMIN R
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: RODMAN & RENSHAW, CO.